Health Care & Life Sciences » Pharmaceuticals | Eyegate Pharmaceuticals Inc.

Eyegate Pharmaceuticals Inc. | Ownership

Companies that own Eyegate Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Armistice Capital LLC
16,802,500
38.68%
0
0.72%
08/03/2018
The Vanguard Group, Inc.
114,949
0.27%
41,000
0%
06/30/2018
Essex Investment Management Co. LLC
73,492
0.17%
73,492
0.01%
06/30/2018
Barclays Capital, Inc.
65,500
0.15%
12,931
0%
06/30/2018
US Bancorp Asset Management, Inc.
40,650
0.09%
0
0%
06/30/2018
IFP Advisors, Inc.
26,800
0.06%
0
0%
06/30/2018
Citadel Advisors LLC
25,851
0.06%
-30,777
0%
06/30/2018
Credit Suisse Securities (USA) LLC (Broker)
22,000
0.05%
-4,500
0%
06/30/2018
Wedbush Securities, Inc. (Investment Management)
20,000
0.05%
0
0%
06/30/2018
Raymond James Financial Services Advisors, Inc.
15,000
0.04%
15,000
0%
06/30/2018

About Eyegate Pharmaceuticals

View Profile
Address
271 Waverley Oaks Road
Waltham Massachusetts 02452
United States
Employees -
Website http://www.eyegatepharma.com
Updated 07/08/2019
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG). OBG is a topically-applied eye drop formulation that is being developed under the 510k De Novo path for devices submitted for marketing clearance to the U.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.